. Actinium-227 decay scheme (1)
NTRODUCTION

METHODS -Overview
Published pharmacokinetic models were used to obtain the distribution of 225/7 Ac -labeled antibody and also the distribution of either free or antibody-conjugated 227 Th. Since 227 Th is obtained from the beta decay branch (99% yield) of 227 Ac rather than a more energetically disruptive alpha-emitter decay, it is possible that a significant fraction of the 227 Th generated remains antibody-conjugated. A pharmacokinetic model representing the distribution of radiolabeled antibody in patients with hematologically distributed cancer is adapted from reference (2) to obtain the pharmacokinetics for 225/7 Ac and 227 Th-labeled antibody. A model representing the pharmacokinetics of free 227 Th is used to model the distribution of unconjugated 227 Th (3). Under both circumstances, 223 Ra generated by 227 Th decay is simulated using a pharmacokinetic model that is relevant to free 223 Ra (4). Calculations were performed assuming 1 kg (10 12 antigen-positive cells) in an adult female. 
METHODS -Biokinetic modeling
CONCLUSIONS
 Using a pharmacokinetic model relevant to treating patients with leukemia and models describing the PK of free thorium and radium, the dose contribution of a 0.7% 227 Ac in accelerator-produced 225 Ac is negligible in the context of therapy; less than 1.4 mGy/MBq for the top 5 highest absorbed tissues and < 0.007 mGy/MBq for all other tissues.
 The conclusions above are specific to the parameter values and assumptions used for antibody targeting of leukemia. They may not apply to lower molecular weight agents or other cancer targets.
